$18.21 0.11 (0.61%)
19:08 EDT MYL Stock Quote Delayed 15 Minutes
Previous Close $18.21
Market Cap 9.75B
PE Ratio -
Volume (Avg. Vol.) 6.98M
Day's Range 18.08 - 18.65
52-Week Range 16.63 - 39.59
Dividend & Yield N/A (N/A)
MYL Stock Predictions, Articles, and Mylan News
- From InvestorPlace
- From the Web
The stock charts of DISH, FFIV and CRM stock are headed into hump-day on the verge of major moves. Here's what you can expect.
The stock charts of CELG, AAL and MYL stock are going to start the new trading week out in a clear technical condition.
Mylan stock is getting smashed after its fourth-quarter earnings results and full-year outlook. MYL stock could still go lower, though.
As Goldman Sachs moves away from the strong balance sheet investing strategy, here are 6 new stocks to buy.
Abbott is about to report another quarter to cap 2018's strong annual performance. ABT stock also offers a dividend for income investors.
Biotech stocks are likely to continue to be volatile in December, but that may create unique buying opportunities.
Mylan stock jumped ahead following quarterly earnings that impressed investors. Management will continue doing better than expected.
Earnings set to the tone for Toyota, CVS Health, Eli Lilly and Mylan as our top stock trades. But midterms will set the tone for the week.
Mylan stock (MYL) is soaring more than 7% after hours Monday as the. company's third-quarter earnings doubled and beat Wall Street estimates.
In the latest EpiPen news, the Food and Drug Administration (FDA) has extended the expiration dates of the allergy medication due to a shortage of EpiPens.
An EpiPen shortage has parents worried as the school season starts back up across the U.S., but there are other options.
MYL stock has been stuck in a downtrend for three-plus years, and nothing about second-quarter numbers imply that this downtrend is ending soon.
Thinking about buying Mylan stock? These are the four risks that you need to understand before taking the plunge
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
Mylan NV (MYL) stock was up on Wednesday following the release of its earnings report for the first quarter of the year.
MYL stock's forward P/E multiples don't reflect the growth potential for the Mylan NV. EpiPen demand and biosimilars will soon give the company a revenue lift.
Once all the Mylan headlines start to sink in, investor perspective could change. That would then move MYL stock that hasn't gone anywhere since February.
RVNC has an edge with its formulation of Botox: it lasts longer. Given the little innovation in the botulinim toxin market, Revance has a real chance to succeed.
From Market News Video
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Fair Isaac Corp (FICO) was identified as having a larger market cap than the smaller end of the S&P 500, for example Mylan NV (MYL), according to The Online Investor. Click here to find out the top S&P 500 components ordered by average analyst rating » Market capitalization is an important data point for investors to keep an eye on, for various reasons..
From Market News Video
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!